Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

UnitedHealth lifts profit outlook as slow elective-care recovery cuts costs

Published 07/15/2022, 05:59 AM
Updated 07/15/2022, 01:17 PM
© Reuters. FILE PHOTO: The corporate logo of the UnitedHealth Group appears on the side of one of their office buildings in Santa Ana, California, U.S., April 13, 2020. REUTERS/Mike Blake
CI
-
CVS
-
UNH
-

By Amruta Khandekar and Manas Mishra

(Reuters) -UnitedHealth Group Inc on Friday raised its annual profit forecast for a second straight quarter, as a slow recovery in non-urgent medical procedures and lower COVID-care costs help it rein in medical expenses.

Shares of the largest U.S. healthcare company by market value rose 4.5% in morning trade, providing the biggest boost to the Dow Jones index.

Health insurers including UnitedHealth (NYSE:UNH) have seen medical costs fluctuate through the pandemic, with lower spending on elective medical procedures softening the blow from higher costs related to COVID-19 testing and treatment.

Defying a trend seen in the last two years of the pandemic, low levels of COVID care was not accompanied by a rapid rise in people going back for deferred procedures or other non-COVID-care services, UnitedHealth Chief Financial Officer John Rex said.

The industry bellweather's comments lifted shares of insurers including Cigna Corp (NYSE:CI), CVS Health (NYSE:CVS) and Elevance Health Inc.

UnitedHealth said it now expects 2022 adjusted profit between $21.40 and $21.90 per share, compared with $21.20 to $21.70 per share forecast earlier.

However, the company cautioned of the impact from a recent uptick in COVID hospitalizations, which had dwindled after the record Omicron-driven surge in January.

"In recent weeks, we are seeing rising COVID-related hospital admissions but with a lower average length of stay compared with earlier periods," Rex said.

UnitedHealth said its outlook accounts for uncertainty related to COVID trends and the possibility of hospitalizations rising again through the year.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The company also said starting from 2023, there would be no copay or out-of-pocket costs for several critical drugs, including insulin for its fully insured members.

The company reported total sales of $80.33 billion, topping estimates of $79.68 billion. Adjusted earnings of $5.57 per share also beat estimates of $5.20 per share.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.